Neuralstem expands enrollment in early-stage study of NSI-566 in spinal cord injury

|By:, SA News Editor

Neuralstem (CUR -0.6%) adds a new cohort of four patients with chronic spinal cord injury to its ongoing Phase 1 clinical trial of NSI-566. Each participant will receive one surgery involving six injections of NSI-566 into the affected area of the cord.

According to, the estimated final data collection date for the primary endpoint of safety is July 2018. The estimated study completion date is December 2022.